India · Delayed Price · Currency is INR Bal Pharma Statistics
Total Valuation
Bal Pharma has a market cap or net worth of INR 1.26 billion. The enterprise value is 2.71 billion.
| Market Cap | 1.26B |
| Enterprise Value | 2.71B |
Important Dates
The last earnings date was Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | Sep 18, 2025 |
Share Statistics
| Current Share Class | 15.92M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.04% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 5.46M |
Valuation Ratios
The trailing PE ratio is 15.47.
| PE Ratio | 15.47 |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| PB Ratio | 1.60 |
| P/TBV Ratio | 2.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 33.42 |
| EV / Sales | 0.88 |
| EV / EBITDA | 10.67 |
| EV / EBIT | 14.28 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.98 |
| Debt / EBITDA | 6.09 |
| Debt / FCF | n/a |
| Interest Coverage | 1.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 8.48% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 6.29% |
| Revenue Per Employee | 3.14M |
| Profits Per Employee | 82,385 |
| Employee Count | 986 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -28.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.09% in the last 52 weeks. The beta is 0.14, so Bal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -16.09% |
| 50-Day Moving Average | 71.92 |
| 200-Day Moving Average | 85.92 |
| Relative Strength Index (RSI) | 70.74 |
| Average Volume (20 Days) | 10,860 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bal Pharma had revenue of INR 3.09 billion and earned 81.23 million in profits. Earnings per share was 4.82.
| Revenue | 3.09B |
| Gross Profit | 1.41B |
| Operating Income | 190.07M |
| Pretax Income | 53.10M |
| Net Income | 81.23M |
| EBITDA | 240.82M |
| EBIT | 190.07M |
| Earnings Per Share (EPS) | 4.82 |
Balance Sheet
The company has 91.26 million in cash and 1.55 billion in debt, with a net cash position of -1.46 billion.
| Cash & Cash Equivalents | 91.26M |
| Total Debt | 1.55B |
| Net Cash | -1.46B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 783.30M |
| Book Value Per Share | 49.68 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 45.42%, with operating and profit margins of 6.14% and 2.62%.
| Gross Margin | 45.42% |
| Operating Margin | 6.14% |
| Pretax Margin | 1.72% |
| Profit Margin | 2.62% |
| EBITDA Margin | 7.78% |
| EBIT Margin | 6.14% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.56%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.56% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.04% |
| Shareholder Yield | -12.49% |
| Earnings Yield | 6.46% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |